profit from every $100 of sales.
$0$100
Seres Therapeutics
$1.56-8.24% today
-88.9% in 1 year
1-year low $1.561-year high $28.63
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $2.79 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Seres Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $789,000 in 2025, with $5.70 million of profit last year.
SalesProfit
Seres Therapeutics vs. similar companies
Seres Therapeutics grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Seres Therapeutics | 2.8× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Seres Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 1 | |
| 0 | 0 | -4 | -6 | |
| -180 | -195 | -121 | -94 | |
| -171 | -181 | -120 | 10 | |
| -250 | -114 | 0 | 6 | |
| -46.20 | -17.77 | 0.00 | 0.64 | |
| – | – | – | -729.4% | |
| – | – | – | -11,910.1% | |
| – | – | – | 721.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 349 | 359 | 140 | 138 |
| Cash | 163 | 128 | 31 | 46 |
| Total debt | 163 | 199 | 92 | 83 |
| Total liabilities | 338 | 403 | 126 | 94 |
| 11 | -45 | 14 | 44 | |
| 5 | 6 | 8 | 9 | |
| -80.9% | -96.3% | -94.2% | 3.5% | |
| -2,319.9% | 253.5% | 1.0% | 12.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -229 | -117 | -149 | 1 | |
| 10 | 8 | 0 | 0 | |
| -239 | -125 | -149 | 1 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 25 | 34 | 21 | 11 |
Valuation
- 2.8×
- –
- –
- 2.8×
- 20.2×
- 18.4×
- 5.4×
- 5.4%
- 35.8%
- 0.0%
Profitability
- -729.4%
- -11,910.1%
- 721.9%
- -4,157.1%
- -80.3%
- -50.0%
- -127.3%
- -39.9%
- -89.2%
- 3,297.1%
Growth
- −72.8%
- –
- +100.6%
- –
- +17.9%
Financial health
- 3.8×
- 3.04
- 68.4%
- –
- 1.65
- 1.65
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 953
Top 1%of 564
Bottom 1%of 871
Top 17%of 988
What analysts expect
- Average price target
- $1.25
- Range
- $1.25 – $1.25
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -2.08 | -1.88 | −10.6% |
| Mar 12, 2026 | -1.89 | -2.39 | +20.9% |
| Nov 5, 2025 | 0.94 | 0.05 | +1,780.0% |
| Aug 6, 2025 | -2.27 | -2.72 | +16.5% |
| May 7, 2025 | -2.24 | -0.67 | −234.3% |
| Mar 13, 2025 | -0.32 | -0.17 | −88.2% |
| Nov 13, 2024 | -6.60 | -5.00 | −32.0% |
| Aug 13, 2024 | -4.40 | -5.60 | +21.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
41No pass
Philip Fisher
32No pass
Peter Lynch
2No pass
Joel Greenblatt
55No pass
Charlie Munger
27No pass
Terry Smith
24No pass
Questions about Seres Therapeutics
Is Seres Therapeutics a good stock to buy?
A business with weak numbers, and the price looks low. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Seres Therapeutics AI analysis
What does Seres Therapeutics do?
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. It is in Biotechnology.
Does Seres Therapeutics pay a dividend?
No. Seres Therapeutics does not pay a dividend at the moment.
Is Seres Therapeutics stock halal?
No. Seres Therapeutics does not pass our halal screen: its debt is 522% of its market value, at or above the 33% limit. How we check
How has Seres Therapeutics stock done over the past year?
Down 88.9% over the past twelve months, to $1.56. It traded between $1.56 and $28.63 and is 94.6% below its high.
Who are Seres Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Seres Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.